Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarithromycin for Non-CF Bronchiectasis in Asian Populations
NCT04658277Unknown
- Sponsor
- The Chinese University of Hong Kong
- Start
- Oct 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of clarithromycin in Non-cystic fibrosis bronchiectasis (NCFB), sponsored by The Chinese University of Hong Kong. Primary endpoint: number of infectious exacerbations at 26 weeks. Status: unknown.
02
Drugs
clarithromycin
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT04658277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04658277.